This development positions the company to potentially capture a share of the RMB3.387 billion pertuzumab injection market in mainland China. The drug is aimed at treating HER2-positive breast ...

(“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for HLX11, a proposed biosimilar to Genentech’s PERJETA. This marks the first U.S. BLA acceptance for a ...

while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous injection and Perjeta as an intravenous infusion, says the CHMP. According to the ...

and Perjeta (pertuzumab) in a subcutaneous injection that takes a few minutes to deliver. At the moment, Herceptin is available as a subcutaneous injection but Perjeta needs to be delivered by ...